December 1, 2016
Following the special consultations on Bill 92 (An Act to extend the powers of the Régie de l’assurance maladie du Québec and to amend various legislative provisions) held last May, the Quebec Health Minister has introduced amendments to be discussed at the committee stage. These amendments are intended to address certain commercial practices around pharmaceutical business.
Operators of private senior’s residence are especially targeted with this amendment.
Pharmacists are also targeted. The followings are just a few of these amendments:
Also noteworthy, one amendment would allow RAMQ to set conditions for the reimbursement of drugs for all listed products on the Quebec list. These conditions would be recommended by INESSS around the concept of optimal use of any given drug.
Also, Bill 92 would allow suspending or delisting of a drug if a manufacturer does not comply with RAMQ pricing requirements and for which there is a therapist substitute.
Bill 92 is in its final stage of review. We will monitor the development of these new amendments as they may impact all of the pharmaceutical stakeholders
For more information contact Ghislain Gauthier, Director, The Pangaea Group